Department of Pediatrics and Child Health, Kurume University School of Medicine, Fukuoka 830-0011, Japan.
Department of Pediatrics, Keio University, Tokyo 160-8582, Japan.
Endocr J. 2020 Aug 28;67(8):853-857. doi: 10.1507/endocrj.EJ20-0011. Epub 2020 Apr 21.
Cytochrome P450 oxidoreductase deficiency (PORD) is a disorder of steroidogenesis that causes various symptoms such as skeletal malformations, disorders of sex development, and adrenal insufficiency. The aim of this study was to elucidate the clinical characteristics, especially age at diagnosis and treatment, of PORD from the perinatal period to adulthood in Japan. The first questionnaire was sent to 183 council members of the Japanese Society for Pediatric Endocrinology on 1 September 2018. The response rate was 65%, and a total of 39 patients with PORD were examined at 20 hospitals. The second questionnaire was sent in November 2018 to the council members examining these 39 patients with PORD. The response rate was 77%, and we received clinical information on 30 of the 39 patients. The two novel clinical findings were the age at diagnosis and the treatment of Japanese patients with PORD. In many cases, PORD can be diagnosed at <3 months of age. Hydrocortisone as the primary treatment during infancy can be used daily or in stressful situations; however, because patients with PORD generally have mild to moderate adrenal insufficiency, some might be able to avoid hydrocortisone treatment. Patients with PORD should be carefully followed up, and treatment should be optimized as for patients with other types of adrenal insufficiency. Other characteristics in the present study were similar to those described in previous reports.
细胞色素 P450 氧化还原酶缺陷症(PORD)是一种类固醇生成障碍性疾病,可导致各种症状,如骨骼畸形、性发育障碍和肾上腺功能不全。本研究旨在阐明日本围生期至成年期 PORD 的临床特征,特别是诊断和治疗年龄。我们于 2018 年 9 月 1 日向日本儿科内分泌学会的 183 名理事会成员发送了第一份问卷,回复率为 65%,共有 20 家医院的 39 名 PORD 患者接受了检查。2018 年 11 月,我们向检查这 39 名 PORD 患者的理事会成员发送了第二份问卷,回复率为 77%,我们收到了 30 名 PORD 患者的临床信息。两项新的临床发现是日本 PORD 患者的诊断和治疗年龄。在许多情况下,PORD 可以在<3 个月大时被诊断出来。氢化可的松作为婴儿期的主要治疗药物,可以每日使用或在应激情况下使用;然而,由于 PORD 患者通常存在轻度至中度的肾上腺功能不全,一些患者可能能够避免氢化可的松治疗。应密切随访 PORD 患者,并根据其他类型的肾上腺功能不全患者优化治疗。本研究中的其他特征与之前的报告描述的相似。